Nirvana Life Sciences Inc.
NIRV
CNSX
10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
---|---|---|---|---|---|
Net Income | 63.95% | 84.89% | 50.70% | 102.30% | 39.95% |
Total Depreciation and Amortization | -- | -- | -73.37% | -47.06% | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -39.94% | -100.06% | -73.92% | -27,150.00% | 5,533.33% |
Change in Net Operating Assets | -91.12% | 66.12% | 264.17% | -35.33% | -62.38% |
Cash from Operations | 59.54% | 98.98% | 91.52% | 65.76% | 40.28% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | 176.47% | -33.75% | 113.90% | -91.45% | -77.22% |
Total Debt Repaid | -- | -- | -- | -- | -100.00% |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -2.82% | -96.22% | -94.01% | -91.33% | -39.06% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 89.32% | -96.31% | -114.75% | -336.36% | 41.94% |